BRIEF-Cassava Sciences Provides A Business Update

Reuters01-08

Jan 7 (Reuters) - Cassava Sciences Inc SAVA.O:

CASSAVA SCIENCES PROVIDES A BUSINESS UPDATE
CASSAVA SCIENCES INC: IMPLEMENTING COST CURTAILMENT INCLUDING A WORKFORCE REDUCTION OF APPROXIMATELY 33%
CASSAVA SCIENCES INC: ESTIMATES THAT IT WILL INCUR APPROXIMATELY $0.4 MILLION OF ONE-TIME COSTS IN Q1 2025 RELATED TO WORKFORCE REDUCTION
CASSAVA SCIENCES INC: IN FINAL STAGES OF DISCONTINUING REFOCUS-ALZ STUDY
CASSAVA- TOPLINE DATA FROM PHASE 3 REFOCUS-ALZ STUDY OF SIMUFILAM IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE EXPECTED LATE Q1/EARLY Q2 2025

Source text: ID:nGNX8hgxHK

Further company coverage: SAVA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501759217?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 06:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501759217","market":"us","top_or_hot":-1,"title":"BRIEF-Cassava Sciences Provides A Business Update","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cassava Sciences Provides A Business Update</title></head><body><p><span>Jan 7 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a> <span>SAVA.O</span>:</p><ul><li><p>CASSAVA SCIENCES PROVIDES A BUSINESS UPDATE</p></li><li><p>CASSAVA SCIENCES INC: IMPLEMENTING COST CURTAILMENT INCLUDING A WORKFORCE REDUCTION OF APPROXIMATELY 33%</p></li><li><p>CASSAVA SCIENCES INC: ESTIMATES THAT IT WILL INCUR APPROXIMATELY $0.4 MILLION OF ONE-TIME COSTS IN Q1 2025 RELATED TO WORKFORCE REDUCTION</p></li><li><p>CASSAVA SCIENCES INC: IN FINAL STAGES OF DISCONTINUING REFOCUS-ALZ STUDY</p></li><li><p>CASSAVA- TOPLINE DATA FROM PHASE 3 REFOCUS-ALZ STUDY OF SIMUFILAM IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE EXPECTED LATE Q1/EARLY Q2 2025</p></li></ul><p>Source text: <span>ID:nGNX8hgxHK</span></p><p>Further company coverage: <span>SAVA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cassava Sciences Provides A Business Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cassava Sciences Provides A Business Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 06:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA4QCJDC:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Cassava Sciences Provides A Business UpdateJan 7 (Reuters) - Cassava Sciences Inc SAVA.O:CASSAVA SCIENCES PROVIDES A BUSINESS UPDATECASSAVA SCIENCES INC: IMPLEMENTING COST CURTAILMENT INCLUDING ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA4QCJDC:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4547","symbol_name":"WSB热门概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nTUA4QCJDC:1","article_id":"2501759217","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501759217","pubTimestamp":1736290179,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cassava Sciences Provides A Business UpdateJan 7 (Reuters) - Cassava Sciences Inc SAVA.O:CASSAVA SCIENCES PROVIDES A BUSINESS UPDATECASSAVA SCIENCES INC: IMPLEMENTING COST CURTAILMENT INCLUDING ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4547":"WSB热门概念","BK4585":"ETF&股票定投概念","SAVA":"Cassava Sciences Inc","BK4588":"碎股","BK4007":"制药"},"translate_title":"简介-Cassava Sciences提供业务更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":0.9},"content_text":"BRIEF-Cassava Sciences Provides A Business UpdateJan 7 (Reuters) - Cassava Sciences Inc SAVA.O:CASSAVA SCIENCES PROVIDES A BUSINESS UPDATECASSAVA SCIENCES INC: IMPLEMENTING COST CURTAILMENT INCLUDING A WORKFORCE REDUCTION OF APPROXIMATELY 33%CASSAVA SCIENCES INC: ESTIMATES THAT IT WILL INCUR APPROXIMATELY $0.4 MILLION OF ONE-TIME COSTS IN Q1 2025 RELATED TO WORKFORCE REDUCTIONCASSAVA SCIENCES INC: IN FINAL STAGES OF DISCONTINUING REFOCUS-ALZ STUDYCASSAVA- TOPLINE DATA FROM PHASE 3 REFOCUS-ALZ STUDY OF SIMUFILAM IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE EXPECTED LATE Q1/EARLY Q2 2025Source text: ID:nGNX8hgxHKFurther company coverage: SAVA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501759217"}